FDA Approves POMALIDOMIDE — Apotex Corp.

# FDA Approves Generic Pomalidomide from Apotex Corp. Apotex Corp. has received FDA approval for its generic version of pomalidomide, an oral immunomodulatory drug used in multiple myeloma treatment, potentially offering significant cost savings as the branded Pomalyst faces increased generic competition. The approval could reshape the competitive landscape for this important cancer therapy, allowing greater market penetration of lower-cost alternatives and potentially impacting pricing dynamics for multiple myeloma patients and payers.